Phenotypic characteristics according to CD56 expression
| . | CD56+ ALCL (n = 25) . | CD56− ALCL (n = 115) . | P value . |
|---|---|---|---|
| ALK | 13/25 (52%) | 68/115 (59%) | .51 |
| CD30 | 25/25 (100%) | 113/115 (98%) | .67 |
| CD15 | 1/22 (5%) | 8/108 (8%) | .52 |
| CD20 | 0/25 | 0/115 | 1.00 |
| CD45RO | 9/18 (50%) | 40/103 (39%) | .37 |
| CD43 | 8/17 (47%) | 49/94 (52%) | .70 |
| CD3 | 11/23 (48%) | 46/101 (46%) | .84 |
| CD4 | 12/22 (55%) | 40/98 (41%) | .24 |
| CD8 | 3/22 (14%) | 13/98 (13%) | .67 |
| EMA | 19/23 (83%) | 85/112 (76%) | .49 |
| BCL2 | 1/8 (13%) | 13/64 (20%) | .51 |
| TIA-1 | 11/22 (50%) | 71/107 (66%) | .15 |
| Granzyme B | 15/25 (60%) | 62/113 (55%) | .64 |
| EBERs | 4/24 (17%) | 8/111 (7%) | .14 |
| . | CD56+ ALCL (n = 25) . | CD56− ALCL (n = 115) . | P value . |
|---|---|---|---|
| ALK | 13/25 (52%) | 68/115 (59%) | .51 |
| CD30 | 25/25 (100%) | 113/115 (98%) | .67 |
| CD15 | 1/22 (5%) | 8/108 (8%) | .52 |
| CD20 | 0/25 | 0/115 | 1.00 |
| CD45RO | 9/18 (50%) | 40/103 (39%) | .37 |
| CD43 | 8/17 (47%) | 49/94 (52%) | .70 |
| CD3 | 11/23 (48%) | 46/101 (46%) | .84 |
| CD4 | 12/22 (55%) | 40/98 (41%) | .24 |
| CD8 | 3/22 (14%) | 13/98 (13%) | .67 |
| EMA | 19/23 (83%) | 85/112 (76%) | .49 |
| BCL2 | 1/8 (13%) | 13/64 (20%) | .51 |
| TIA-1 | 11/22 (50%) | 71/107 (66%) | .15 |
| Granzyme B | 15/25 (60%) | 62/113 (55%) | .64 |
| EBERs | 4/24 (17%) | 8/111 (7%) | .14 |
See Table 2 for explanation of abbreviations.